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In the current era of immunosuppressive medications there is increased observed incidence of graft dysfunction in the absence
of known histological criteria of rejection after heart transplantation. A noninvasive molecular expression diagnostic test was
developed and validated to rule out histological acute cellular rejection. In this paper we present for the ﬁrst time, longitudinal
pattern of changes in this novel diagnostic test score along with QTc-interval in a patient who was admitted with unexplained graft
dysfunction. Patient presented with graft failure with negative ﬁndings on all known criteria of rejection including acute cellular
rejection, antibody mediated rejection and cardiac allograft vasculopathy. The molecular expression test score showed gradual
increase and QTc-interval showed gradual prolongation with the gradual decline in graft function. This paper exempliﬁes that in
patients presenting with unexplained graft dysfunction, GEP test score and QTc-interval correlate with the changes in the graft
function.
1.Introduction
Cardiac allograft rejection after heart transplantation (HTx)
can involve both cellular and antibody mediated immune
injury to the allograft. Hyperacute rejection is an antibody-
mediated process which occurs typically minutes to hours
after transplantation. Acute cellular rejection (ACR) is a
T-lymphocyte mediated process that occurs from the ﬁrst
week to years after HTx and is the major cause of graft
loss early after HTx although its incidence declines after
ﬁrst year [1]. ACR is diagnosed by endomyocardial biopsy
(EMB) and graded by degree of lymphocyte inﬁltration into
myocardium according to International Society of Heart
and Lung Transplantation (ISHLT) guidelines [2, 3]. Acute
antibody mediated rejection (AMR) was reported to be
present in 2% to 20% of EMBs after heart transplantation
[1, 4–8]. It is classically demonstrated by linear deposition of
immunoglobulins and complement splitting products such
as C4d in the vascular endothelium [8]. Cardiac allograft
vasculopathy (CAV) is one of the major causes of late
graft dysfunction (GD). It is diagnosed by annual coronary
angiography or intravascular ultrasound (IVUS). Histori-
cally invasive EMB was only indicated based on the clinical
suspicion of rejection assessed by electrocardiographic and
hemodynamic parameters. Recently, using postgenome-era
high-throughput transcriptomic technology, a novel non-
invasive molecular expression diagnostic test was developed
and validated against EMB based criteria of ACR [9]. This
peripheral blood mononuclear cell gene expression proﬁling
( G E P )t e s tw i t has c o r e<34 has very high negative predictive
value of 99.6% to rule out moderate/severe (≥2R/3A) ACR
[10].Withtheadvancementintheimmunosuppressivemed-
ications in the transplantation medicine, there is increased
observed incidence of unexplained graft dysfunction in HTx
patients. In this paper we present for the ﬁrst time the role
of longitudinal patterns of this novel molecular expression
test and QTc-interval in a patient admitted with unexplained
graft dysfunction.2 Cardiology Research and Practice
2. Case Presentation
A 59-year-old gentleman with a history of ischemic car-
diomyopathy underwent orthotopic heart transplantation in
our center on October 10, 2005. The donor was a 36-year-
o l dm a l em a t c h e df o rb o d ys i z ew i t hn e g a t i v es e r o l o g i e s
for Cytomegalovirus and Toxoplasma. Postoperatively, his
overallcoursewasstableandfollowedwithEMBwithoutsig-
niﬁcant history of ACR. During the ﬁrst 6 months rejection
monitoring was EMB based. After the 9th month, we tran-
sitioned to non-invasive GEP test based monitoring [9]o n
the basis of consensus recommendations [10]. In the overlap
phase (concomitant invasive and non-invasive monitoring),
anEMBonJune6,2006,showedabsenceofrejection(Quilty
lesions) with a GEP test score of 26, right atrial pressure of
5mmHg, pulmonary artery pressures of 31mmHg systolic,
11mmHg diastolic, and a mean of 22, pulmonary capillary
wedgepressureof13,anO2 mixedvenoussaturationof75%,
and a cardiac output (CO) by thermodilution of 5.86l/min
(Cardiac Index 2.55l/min/sqm). A follow up biopsy on
January 11, 2007 showed ISHLT grade 0 with a GEP score
of 28 (Table 1). From that time on, the patient was followed
non-invasively with the GEP test and echocardiography and
had a clinically stable course until January 2008. A follow
up echocardiogram obtained on January 17, 2008 showed
reduction in left ventricular ejection fraction (LVEF) from
normal to 43%. The patient’s immunosuppressive regimen
at that moment included cyclosporine (CsA) 100mg twice a
day, mycophenolate 250mg twice a day and prednisone 5mg
daily. In addition, the patient was also receiving pravastatin
20mg, aspirin 81mg, doxazosin 1mg, amlodipine 2.5mg
and carvedilol 25mg.
On January 29 2008, the patient presented to our
clinic with atypical chest pain, shortness of breath, and
hemoptysis. His Initial evaluation revealed blood pressure
of 120/80mmHg, heart rate 92bpm regular, temperature
98.7, and respiratory rate of 22. His NYHA functional class
was III-IV, his lung auscultation was remarkable for bilateral
crackles, and his heart auscultation was positive for an S3
gallop. The abdomen was soft without organomegaly and
the patient had no lower extremity edema. A chest X-
ray showed new extensive right perihilar disease. An EKG
showed no acute changes but his QTc-interval duration
was 530ms. Right heart catheterization and an EMB were
done emergently. Hemodynamics showed Pulmonary Artery
(S/D/M): 62/33/45, Pulmonary Capillary Wedge (a/v/M):
34/47/39, Right Atrium (a/v/M): 16/14/13, a Mixed Venous
O2 Saturation of 51% and CO by thermodilution of
3.20l/min (Cardiac Index = 1.38l/min/sqm).
The review of the patient posttransplant management
during the last year showed a progressive declination of the
graft function within the range of normality values (Table 1),
prolongation of the QTc-interval on the EKG, and progres-
sive increase in his GEP scores (Figure 1). After the clinically
indicated EMB, patient was treated with intravenous steroids
under the presumed diagnosis of ACR. The EMB showed
focal, mild (1A/1R) ACR with nodular endocardial inﬁltrate
(Quilty eﬀect). A C4d immunohistochemical staining was
negative for AMR. Respiratory viral panels were negative,
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Figure 1: Longitudinal post-HTx changes in the GEP test score,
QTc-interval, and Left Ventricular Ejection Fraction. L = left axis;
R = right axis; LVEF = left ventricular ejection fraction; GEP = gene
expression proﬁling test score; QTc = corrected QT interval.
and viral inclusions or associated inﬂammatory response
was not found on the EMB. The patient was treated with
intravenous (pulse) methyl-prednisolone for three consecu-
tive days (500milligrams per day) followed by an oral taper
of methyl-prednisone in addition to diuretics. A coronary
angiogram done on February 05, 2008 showed mild pruning
of the distal coronary arteries. A follow-up echocardiogram
4 days after completing treatment showed improvement in
regional wall motion abnormality and a signiﬁcant increase
in the LVEF to 40%–45%. The patient was discharged
home in a stable condition. On 03/04/2008, a follow-up
EMB and right heart catheterization were obtained which
showedimpairedgraftfunctionand1A/1Rbiopsygradewith
negative C4d staining. The patient was treated with intra-
venous methyl-prednisolone (500mg) and a steroid taper.
New evaluation with EMB on 04/07/2008 showed absence
of lymphocytic inﬁltrates or C4d deposition. Subsequent
evaluation of the graftfunction by echocardiography showed
persistent allograft dysfunction (Table 1).
3. Discussion
There were no ﬁndings consistent with ACR and AMR in
our case. CAV is present in about half of all HTx recipients
at 5 years posttransplantation. Although our patient had
evidence of mild pruning of the distal coronary vessels on
the angiography but there was no signiﬁcant blockage of any
of the main vessels. These angiographic ﬁndings were unable
to explain the degree of graft dysfunction.
Infectious etiologies are a potential cause for primary or
secondary allograft dysfunction during the ﬁrst years after
transplantation with cytomegalovirus as the most common
etiologic agent [11]. Repetitive blood cultures and PCR
analyses and the absence of intranuclear inclusions in the
endomyocardial samples made this possibility very unlikely.
Considering the initial presentation of the patient with acute
respiratory inﬁltrates would raise the consideration of aCardiology Research and Practice 3
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severe systemic acute infection, potentially of viral origin
leading to graft loss which has been increasingly reported
[12]. An inﬁltrative myocardial disease of the recipient could
be suspected such as amyloidosis or lymphoproliferative
disease aﬀecting the heart. Post-HTx lymphoproliferative
disease has been reported to have tropism for the trans-
planted organs and to be a cause of cardiac allograft failure
[13]. Neither the clinical ﬁndings during this admission nor
the biopsy raised this suspicion.
In the present case, the review of his medical his-
tory showed progressive declination of the graft function
within the range of normality, with partial improvement
after steroid treatment that suggests an acute inﬂammatory
alloimmune mechanism with a negative biopsy. EMB has
been used for the last 35 years to screen patients for ACR
although it has been limited by invasiveness, complexity,
discomfort, complication-proneness, interpretation variabil-
ity and late detection of rejection. In the current era and
state of practice in HTx, the limitations of EMB have been
recalled. The likelihood of consensus for the diagnosis of
ACR in eyes of highly experienced pathologist is less than
expected with 78% best agreement rate for 3A/2R rejection
and signiﬁcantly lower for grades 1B/1R, 1A/1R, and 2/1R.
There is 50% downgrading of rejection grade when an
independent local pathologist reading is reinterpreted by a
core of expert pathologists [14].
In original CARGO study, the cutoﬀ of 34 on the
GEP test score scale was selected to adjust for the high
negative predictive value (NPV) of the test with the intention
to rule out ACR. In our patient, GEP test score mostly
remained in the lower 30s range. This could be explained
by the absence of documented evidence of moderate/severe
ACR as deﬁned by histology (≥2R/3A) against which GEP
test was developed and validated. Most recently, we have
analyzed the variability of the molecular score within and
between patients suggesting that not only a cutoﬀ value
is important but the time dependent variability of the
molecular score may provide a more personalized evaluation
[15]. Furthermore, data from CARGO study showed that
independently from the cut-oﬀ value set for the purpose of
the study, as the agreement of rejection diagnosis increased
among pathologists, also did the molecular score [9].
In the post implementation clinical experience of GEP
test we have demonstrated the relationship of the GEP
test score with echocardiographic and electrocardiographic
parameters of allograft rejection [16]. In the present case,
longitudinal evaluation of the results of the GEP test
suggested a progressive increase in the molecular score from
a deep quiescent range to an alloactivated status. The time
dependent and sustained trend of the molecular test showed
a signiﬁcant variability that followed the progressive left
ventricular function deterioration, prolongation of the QTc-
interval, and development of acute decompensated graft
failure that lead to hospitalization. The presentation of GD
without histological evidence of signiﬁcant ACR, absence of
C4d deposition, and other surrogates of rejection suggest
the limitation of currently available diagnostic tools. With
thefailureofcurrentlyknownhistopathologicalmechanisms
to explain the involved immune mechanisms there is need
to develop accurate methods beyond histological criteria to
detect/predict patients with unexplained graft dysfunction.
4. Conclusion
Thiscasereportexempliﬁesthatinpatientswithunexplained
graft dysfunction, GEP test score and QTc-interval correlate
with the changes in the graft function. These patients are
empirically treated as rejection or even infection without
an objective proof to support the diagnosis or treatment
for these severe life threatening conditions. Furthermore,
we use medical treatments that may lead to severe adverse
events without exactly knowing which the entity that we are
treating is. Further studies are required to better understand
the immune mechanisms of unexplained GD and to develop
accurate diagnostic tools beyond histological criteria for
appropriate treatment interventions.
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